NCT03602976View on ClinicalTrials.gov

Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

August 20, 2018

Primary Completion Date

January 12, 2022

Study Completion Date

January 12, 2022

Conditions
Hepatic Sarcoidosis, Elevated Alkaline Phosphatase
Interventions
DRUG

Ursodeoxycholic Acid

weight-based dosing

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

Meridian Bioscience, Inc.
All Listed Sponsors
collaborator

American Association for the Study of Liver Diseases

OTHER

collaborator

Meridian Bioscience, Inc.

INDUSTRY

lead

Ethan Weinberg

OTHER

NCT03602976 - Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis | Biotech Hunter | Biotech Hunter